COMMUNIQUÉS West-GlobeNewswire

Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients With DMD in PhaseOut DMD Clinical Trial

20/11/2017 - 13:00

OXFORD, United Kingdom, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Summit Continues to Expect 24-week Data Q1 2018, which Could Provide Potential Proof of Mechanism for Ezutromid Oxford, UK, 20 November 2017 – Summit [...]

Protalix BioTherapeutics Announces Presentation to be made at the New Horizons in Fabry Disease Conference

20/11/2017 - 13:00

CARMIEL, Israel, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE: PLX ) announced today two-year results from the phase I/II open-label extension clinical trial of [...]

Recro Pharma Secures $100 Million Credit Facility

20/11/2017 - 13:00

Proceeds Provide Funding for IV Meloxicam 30mg Approval Milestone Interest-only Structure Allows for Reinvestment of CDMO Cash Flows in Value Accretive Commercial Activities Substantial Reduction in the Company’s Cost [...]

ZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology Annual Meeting

20/11/2017 - 13:00

– Controlled IL-12 gene therapy turns cold tumors hot – – MRI indicates decreasing size of brain tumor lesions in several patients – – Median overall survival for patients with recurrent glioblastoma (rGBM) maintained [...]

TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer

20/11/2017 - 13:00

ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status Approval supported by robust data from a randomized, well-controlled Phase 3 [...]

ProQR Announces Results for the Third Quarter of 2017

20/11/2017 - 13:00

Key updates Runway into the second half of 2019: cash of €39.7 million at end of Q3, increased by gross proceeds of approximately $20 million from an issuance of ordinary shares in November 2017 that will fund [...]

Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

20/11/2017 - 13:00

GAITHERSBURG, Md., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ( [...]

Kamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin Deficiency

20/11/2017 - 13:00

Following Kamada’s Recent Withdrawal of European Marketing Authorization Application, Distribution Agreement Not Currently Warranted REHOVOT, Israel, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA ) (TASE: [...]

Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia

20/11/2017 - 13:00

NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI ), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today [...]

Amphastar Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference

20/11/2017 - 12:00

RANCHO CUCAMONGA, Calif., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH ) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 29th Annual Piper [...]

Orphazyme A/S: Completion of the Offering and registration of share capital increase

20/11/2017 - 11:46

Company announcement No. 12/2017 Orphazyme A/S Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 20 November 2017 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART [...]

TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

20/11/2017 - 09:32

PRESS RELEASE TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting Leuven (BELGIUM) - November 20, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced [...]

TiGenix présentera les données favorables de la semaine 52 de l'essai de phase III de Cx601 à l'occasion de l'EHA-SWG Scientific Meeting

20/11/2017 - 09:32

COMMUNIQUÉ DE PRESSE TiGenix présentera les données favorables de la semaine 52 de l'essai de phase III de Cx601 à l'occasion de l'EHA-SWG Scientific Meeting Louvain (BELGIQUE) - 20 novembre 2017, 07h. CET - TiGenix NV [...]

Veritas’ Research Arm Cannevert Therapeutics Signs Letter of Intent with Fundación de Investigación (FDI) of Puerto Rico USA to Begin Human Trials of Its Lead Cannabis Strain for Pain

20/11/2017 - 09:05

VANCOUVER, British Columbia, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ), (“Veritas” or the “Company”) announces that its research arm, Cannevert Therapeutics Ltd. ("CTL [...]

Orphazyme A/S: No termination or withdrawal of Orphazyme's IPO

20/11/2017 - 08:39

Company announcement No. 11/2017 Orphazyme A/S Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 20 November 2017 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART [...]

Prima BioMed Changes Its Name to Immutep Ltd

20/11/2017 - 07:59

SYDNEY, Australia, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) has announced a rebranding of the Company from Prima BioMed Ltd to Immutep Ltd (“Immutep”) [...]

Novartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children

20/11/2017 - 07:16

Tasigna is the first and only second-generation tyrosine kinase inhibitor approved in the EU for the treatment of Ph+ CML-CP in children Approval builds on a series of Tasigna regulatory milestones, including addition [...]

MDxhealth teams up with Pharmaceutical Company Ferrer for distribution of its Prostate Cancer test SelectMDx in Spain

20/11/2017 - 07:01

Promising market with an estimate of over 300.000 Spanish men with elevated PSA levels MDxHealth's urine test a non-invasive, molecular test clearly showing who could safely forego a painful biopsy, saving patients from [...]

MDxhealth fait équipe avec la société pharmaceutique Ferrer pour distribuer SelectMDx en Espagne

20/11/2017 - 07:01

Marché prometteur avec un nombre estimé de 300.000 hommes espagnols avec un taux de PSA élevé Le test urinaire moléculaire non-invasif de MDxHealth démontre clairement qui peut renoncer à une biopsie douloureuse en [...]